Execution risk in product approvals for Pune facility
Ramp-up of SPL Infusion depends on obtaining approvals for 23-24 products; delays could impact revenue targets.
SANJIVANIPARANTERAL / Q3-FY26 / risks
Keep the risk register visible.
Sanjivani Paranteral · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Margin volatility from product mix shifts
Management acknowledged that quarterly margins can fluctuate due to product mix, which may affect predictability.
Geopolitical and logistics disruptions
Past logistics issues due to geopolitical tensions have been resolved, but any recurrence could impact export shipments.
Low promoter shareholding
An analyst raised concern about promoter shareholding being low; management indicated gradual increases but no specific target.